Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation
of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an
intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood
vessels more visible in scans. The goal of this trial is to learn if CESM, is better than
standard mammography in quickly and efficiently determining the cause of nipple discharge and
detecting breast cancer, if present. CESM may increase the chance of finding breast cancers
and lower the risk of having unnecessary biopsies.